Keppra: Difference between revisions
From Glioblastoma Treatments
Jump to navigationJump to search
(Created page with "{{TreatmentInfo |drug_name=Keppra (Levetiracetam) |FDA_approval=Yes (as an anti-seizure medication, 1999) |used_for=Seizure prevention in brain tumor patients, potential sensitizer for glioblastoma cells to temozolomide chemotherapy |clinical_trial_phase=Retrospective studies and laboratory research |common_side_effects=Common side effects associated with Keppra include fatigue, dizziness, and mood changes, but it is generally well-tolerated in the context of brain tumor...") |
No edit summary |
||
| Line 13: | Line 13: | ||
|category=Repurposed Drugs | |category=Repurposed Drugs | ||
|links= | |links= | ||
|toxicity_level=2 | |||
|toxicity_explanation=Keppra (Levetiracetam) is generally well-tolerated when used in the treatment of glioblastoma. Its side effects including fatigue, dizziness, and mood changes are fairly mild. However, like all medication, it does come with some level of toxicity which is why it's ranked at a 2 on a scale of 1 to 5. It's important to always discuss potential side effects with your healthcare provider to ensure this treatment is a good fit for you. | |||
}} | }} | ||
Revision as of 08:51, 27 March 2024
| Property | Information |
|---|---|
| Drug Name | Keppra (Levetiracetam) |
| FDA Approval | Yes (as an anti-seizure medication, 1999) |
| Used for | Seizure prevention in brain tumor patients, potential sensitizer for glioblastoma cells to temozolomide chemotherapy |
| Clinical Trial Phase | Retrospective studies and laboratory research |
| Clinical Trial Explanation | Not specified |
| Common Side Effects | Common side effects associated with Keppra include fatigue, dizziness, and mood changes, but it is generally well-tolerated in the context of brain tumor treatment. |
| OS without | Median OS for glioblastoma patients not taking Keppra: 16.7 months |
| OS with | Median OS for glioblastoma patients taking Keppra during chemotherapy: 25.7 months |
| PFS without | Median PFS for patients not taking Keppra: 6.7 months |
| PFS with | Median PFS for patients taking Keppra: 9.4 months |
| Usefulness Rating | 4 |
| Usefulness Explanation | Not specified |
| Toxicity Level | 2 |
| Toxicity Explanation | Keppra (Levetiracetam) is generally well-tolerated when used in the treatment of glioblastoma. Its side effects including fatigue, dizziness, and mood changes are fairly mild. However, like all medication, it does come with some level of toxicity which is why it's ranked at a 2 on a scale of 1 to 5. It's important to always discuss potential side effects with your healthcare provider to ensure this treatment is a good fit for you. |
Notes: Keppra has become a prevalent choice for seizure prevention in brain tumor patients, with emerging evidence suggesting it can also enhance the efficacy of temozolomide chemotherapy by inhibiting MGMT enzyme activity. Significant increases in progression-free and overall survival were observed in patients receiving Keppra alongside chemotherapy in a retrospective study. Further research is needed to understand the full scope of benefits and whether they extend to patients with unmethylated MGMT status.
From Ben Williams Book: Not specified
Loading comments...
